Indication

Clostridium perfringens empyema

*Clostridium perfringens* empyema is a rare, severe pleuropulmonary infection characterized by the accumulation of purulent, exudative fluid within the pleural cavity caused by the anaerobic, spore-forming bacillus *Clostridium perfringens*. Read more about Clostridium perfringens empyema

36 drugs 24 manufacturers

Advertisement

Drugs that treat it

Common Clostridium perfringens empyema therapies.

Showing 19–27 of 36 drugs

Filter & compare in the drug finder →Opens the drug finder with Clostridium perfringens empyema preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Clostridium perfringens empyema.

*Clostridium perfringens* empyema is a rare, severe pleuropulmonary infection characterized by the accumulation of purulent, exudative fluid within the pleural cavity caused by the anaerobic, spore-forming bacillus *Clostridium perfringens*.

It primarily affects the respiratory and pleural systems, occurring most frequently in adults with underlying vulnerabilities such as thoracic trauma, recent invasive thoracic or abdominal surgery, oropharyngeal aspiration, or transdiaphragmatic and hematogenous translocation from a gastrointestinal source.

Pathophysiologically, the organism proliferates in hypoxic pleural tissue and elaborates destructive exotoxins that drive tissue necrosis, prominent neutrophil infiltration, and rapid gas production, often leading to loculated effusions, hydropneumothorax, and severe systemic toxicity.

Personalize your experience

Follow Clostridium perfringens empyema and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it